

Reference:	FOI.13428.23
Subject:	Cancer treatments
Date of Request:	15 December 2023

Requested:

1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?

- Ipilimumab (monotherapy)
- Nivolumab (monotherapy)
- Nivolumab AND Ipilimumab (combination)
- Pembrolizumab
- Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of Renal cell carcinoma?

- Nivolumab (monotherapy)
- Nivolumab + Ipilimumab
- Nivolumab + Cabozantinib
- Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

3. In the past 3 months, how many patients have been initiated* on the following agents for treatment for Advanced/Metastatic Oesophageal Cancer:

- Nivolumab monotherapy or in combination with Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Response:

1. Hywel Dda University Health Board (UHB) provides, within the table below, the number of melanoma patients that have been initiated with the listed medications, during the period 1 September to 30 November 2023.

Medication	Number
Ipilimumab (monotherapy)	0
Nivolumab (monotherapy)	*
Nivolumab AND Ipilimumab (combination)	*
Pembrolizumab	*
Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)	0
Other active systemic anti-cancer therapy	0

2. The UHB provides, within the table below, the number of Renal Cell Carcinoma patients that have been initiated with the listed medications, during the period 1 September to 30 November 2023.

Medication	Number
Nivolumab (monotherapy)	*
Nivolumab + Ipilimumab	0
Nivolumab + Cabozantinib	0
Avelumab + Axitinib	0

3. The UHB provides, within the table below, the number of patients with Advanced/Metastatic Oesophageal Cancer, that have been initiated with the listed medications, during the period 1 September to 30 November 2023

Medication	Number
Nivolumab monotherapy or in combination with Ipilimumab	0
Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	*
Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)	*

Where the figures in the tables have been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (less than 5), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the FoIA. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations, as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.